The further work required to establish sphingolipids as a biomarker of prediabetes risk is discussed by Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA).
The abstract ‘Association of Ceramide and Sphingolipid Species with Incident Prediabetes among Offspring of Parents with Type 2 Diabetes’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- What needs to be done to establish sphingolipids as a biomarker of prediabetes risk? (0:40)
- What are the next steps in your research? (4:18)
Disclosures: Samuel Dagogo-Jack has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!